Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study

Fig. 1

Screen failure and CTP selection reasons. Reasons for screen failures: There was a total of 23 screen failures, with 12 patients not meeting inclusion or meeting exclusion criteria, and 11 not consented for other reasons. “Not feasible” refers to family not consenting because of visit schedule or travel time required to reach to study site. Reasons for choice of CTP: The number of patients treated with each of the CTPs is shown in bold text below the CTP. The physician and patient/family jointly decided upon which CTP to use, and could choose more than one reason for their selection. The reasons for CTP selection are listed, and in the same row the corresponding number (%) of patients enrolled for each reason within each of the three CTPs is shown. Not shown are concerns about patient compliance (n = 1, CTP B, 4%), or insurance issues (n = 0). CTP: consensus treatment plan; IV CS: intravenous corticosteroid (methylprednisolone); jLS: juvenile localized scleroderma; mo: month; MTX: methotrexate; n: number of patients; rx: treatment; PO CS: oral corticosteroid (prednisone or prednisolone)

Back to article page